Frank C. Sciavolino
Co-Founder, President and CSO
Drugs similar to existing therapies
Thetis Pharmaceuticals LLC
United States of America
Biography
Dr. Sciavolino has extensive experience in the pharmaceutical industry including a distinguished 35 year career at Pfizer Global R&D where he held various management roles and responsibilities in R&D operations including drug discovery, development, registration and licensing. Dr. Sciavolino served as Director of R&D operations at Pfizer, where he led the discovery of Zithromax and played a major role in the COX-2 technology and Celebrex development and registration. He also had a leadership role in setting up Pfizer’s R&D operations in Japan. Dr. Sciavolino has served on numerous editorial boards including Annual Reports in Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and the Journal of Antibiotics. Dr. Sciavolino has more than 30 issued patents and has a Ph.D. in organic chemistry from the University of Michigan and B.S. in Pharmacy from St. John’s University.
Research Interest
Novel small molecule drugs to treat inflammatory bowel disease (IBD) based on a unique paradigm of resolving inflammation
